Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 398


Inhibiting Pathways Predicted From a Steroid Hormone Gene Signature Yields Synergistic Antitumor Effects in NSCLC.

Almotlak AA, Farooqui M, Siegfried JM.

J Thorac Oncol. 2019 Oct 10. pii: S1556-0864(19)33523-3. doi: 10.1016/j.jtho.2019.09.195. [Epub ahead of print]


Dalbavancin Use in the Emergency Department Setting.

Patel M, Smalley S, Dubrovskaya Y, Siegfried J, Caspers C, Pham V, Press RA, Papadopoulos J.

Ann Pharmacother. 2019 Nov;53(11):1093-1101. doi: 10.1177/1060028019855159. Epub 2019 Jun 3.


Lung Adenocarcinoma Syndecan-2 Potentiates Cell Invasiveness.

Tsoyi K, Osorio JC, Chu SG, Fernandez IE, De Frias SP, Sholl L, Cui Y, Tellez CS, Siegfried JM, Belinsky SA, Perrella MA, El-Chemaly S, Rosas IO.

Am J Respir Cell Mol Biol. 2019 Jun;60(6):659-666. doi: 10.1165/rcmb.2018-0118OC.


Posaconazole versus voriconazole as antifungal prophylaxis during induction therapy for acute myelogenous leukemia or myelodysplastic syndrome.

Phillips K, Cirrone F, Ahuja T, Siegfried J, Papadopoulos J.

J Oncol Pharm Pract. 2019 Mar;25(2):398-403. doi: 10.1177/1078155218806975. Epub 2018 Oct 14.


Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer.

Miranda O, Farooqui M, Siegfried JM.

Cancers (Basel). 2018 Aug 21;10(9). pii: E280. doi: 10.3390/cancers10090280. Review.


Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer.

Garon EB, Siegfried JM, Stabile LP, Young PA, Marquez-Garban DC, Park DJ, Patel R, Hu EH, Sadeghi S, Parikh RJ, Reckamp KL, Adams B, Elashoff RM, Elashoff D, Grogan T, Wang HJ, Dacic S, Brennan M, Valdes Y, Davenport S, Dubinett SM, Press MF, Slamon DJ, Pietras RJ.

Lung Cancer. 2018 Sep;123:91-98. doi: 10.1016/j.lungcan.2018.06.013. Epub 2018 Jun 22.


STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Non-Small Cell Lung Cancer.

Njatcha C, Farooqui M, Kornberg A, Johnson DE, Grandis JR, Siegfried JM.

Mol Cancer Ther. 2018 Sep;17(9):1917-1926. doi: 10.1158/1535-7163.MCT-17-1194. Epub 2018 Jun 11.


Gene Promoter Hypermethylation Detected in Sputum Predicts FEV1 Decline and All-Cause Mortality in Smokers.

Leng S, Diergaarde B, Picchi MA, Wilson DO, Gilliland FD, Yuan JM, Siegfried JM, Belinsky SA.

Am J Respir Crit Care Med. 2018 Jul 15;198(2):187-196. doi: 10.1164/rccm.201708-1659OC.


Multilayer Model of Pharmacy Participation in the Antimicrobial Stewardship Program at a Large Academic Medical Center.

Dubrovskaya Y, Scipione MR, Siegfried J, Jen SP, Pham V, Papadopoulos J, Decano A, Lewis T, Dabestani A.

Hosp Pharm. 2017 Oct;52(9):628-634. doi: 10.1177/0018578717726993. Epub 2017 Aug 29.


Preclinical Evidence for Combined Use of Aromatase Inhibitors and NSAIDs as Preventive Agents of Tobacco-Induced Lung Cancer.

Stabile LP, Farooqui M, Kanterewicz B, Abberbock S, Kurland BF, Diergaarde B, Siegfried JM.

J Thorac Oncol. 2018 Mar;13(3):399-412. doi: 10.1016/j.jtho.2017.11.126. Epub 2017 Dec 9.


Adherence to surveillance guidelines in resected NSCLC: Physician compliance and impact on outcomes.

Ho C, Siegfried J, Remo K, Laskin J.

Lung Cancer. 2017 Oct;112:176-180. doi: 10.1016/j.lungcan.2017.08.012. Epub 2017 Aug 19.


Gene methylation biomarkers in sputum as a classifier for lung cancer risk.

Leng S, Wu G, Klinge DM, Thomas CL, Casas E, Picchi MA, Stidley CA, Lee SJ, Aisner S, Siegfried JM, Ramalingam S, Khuri FR, Karp DD, Belinsky SA.

Oncotarget. 2017 Jul 15;8(38):63978-63985. doi: 10.18632/oncotarget.19255. eCollection 2017 Sep 8.


Lung Endothelial MicroRNA-1 Regulates Tumor Growth and Angiogenesis.

Korde A, Jin L, Zhang JG, Ramaswamy A, Hu B, Kolahian S, Guardela BJ, Herazo-Maya J, Siegfried JM, Stabile L, Pisani MA, Herbst RS, Kaminski N, Elias JA, Puchalski JT, Takyar SS.

Am J Respir Crit Care Med. 2017 Dec 1;196(11):1443-1455. doi: 10.1164/rccm.201610-2157OC.


Clinical Utility of Chromosomal Aneusomy in Individuals at High Risk of Lung Cancer.

Barón AE, Kako S, Feser WJ, Malinowski H, Merrick D, Garg K, Malkoski S, Pretzel S, Siegfried JM, Franklin WA, Miller Y, Wolf HJ, Varella-Garcia M.

J Thorac Oncol. 2017 Oct;12(10):1512-1523. doi: 10.1016/j.jtho.2017.06.008. Epub 2017 Jun 19.


Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.

Tarhini AA, Rafique I, Floros T, Tran P, Gooding WE, Villaruz LC, Burns TF, Friedland DM, Petro DP, Farooqui M, Gomez-Garcia J, Gaither-Davis A, Dacic S, Argiris A, Socinski MA, Stabile LP, Siegfried JM.

Cancer. 2017 Aug 1;123(15):2936-2944. doi: 10.1002/cncr.30717. Epub 2017 May 4.


Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer.

Siegfried JM, Farooqui M, Rothenberger NJ, Dacic S, Stabile LP.

Oncotarget. 2017 Apr 11;8(15):24063-24076. doi: 10.18632/oncotarget.16030.


Role of postgraduate year 2 pharmacy residents in providing weekend antimicrobial stewardship coverage in an academic medical center.

Siegfried J, Merchan C, Scipione MR, Papadopoulos J, Dabestani A, Dubrovskaya Y.

Am J Health Syst Pharm. 2017 Mar 15;74(6):417-423. doi: 10.2146/ajhp160133.


Myeloid STAT3 Promotes Lung Tumorigenesis by Transforming Tumor Immunosurveillance into Tumor-Promoting Inflammation.

Zhou J, Qu Z, Sun F, Han L, Li L, Yan S, Stabile LP, Chen LF, Siegfried JM, Xiao G.

Cancer Immunol Res. 2017 Mar;5(3):257-268. doi: 10.1158/2326-6066.CIR-16-0073. Epub 2017 Jan 20.


Boron Trifluoride Gas Adsorption in Metal-Organic Frameworks.

Siu PW, Siegfried JP, Weston MH, Fuller PE, Morris W, Murdock CR, Hoover WJ, Richardson RK, Rodriguez S, Farha OK.

Inorg Chem. 2016 Dec 5;55(23):12110-12113. Epub 2016 Nov 17.


Multidrug-Resistant Bacteroides fragilis Bacteremia in a US Resident: An Emerging Challenge.

Merchan C, Parajuli S, Siegfried J, Scipione MR, Dubrovskaya Y, Rahimian J.

Case Rep Infect Dis. 2016;2016:3607125. doi: 10.1155/2016/3607125. Epub 2016 Jun 23.


A prospective and retrospective analysis of smoking behavior changes in ever smokers with high risk for lung cancer from New Mexico and Pennsylvania.

Leng S, Weissfeld JL, Picchi MA, Styn MA, Claus ED, Clark VP, Wu G, Thomas CL, Gilliland FD, Yuan J, Siegfried JM, Belinsky SA.

Int J Mol Epidemiol Genet. 2016 Jun 1;7(2):95-104. eCollection 2016.


ATM protein is deficient in over 40% of lung adenocarcinomas.

Villaruz LC, Jones H, Dacic S, Abberbock S, Kurland BF, Stabile LP, Siegfried JM, Conrads TP, Smith NR, O'Connor MJ, Pierce AJ, Bakkenist CJ.

Oncotarget. 2016 Sep 6;7(36):57714-57725. doi: 10.18632/oncotarget.9757.


KRAS and TP53 mutations in bronchoscopy samples from former lung cancer patients.

Gao W, Jin J, Yin J, Land S, Gaither-Davis A, Christie N, Luketich JD, Siegfried JM, Keohavong P.

Mol Carcinog. 2017 Feb;56(2):381-388. doi: 10.1002/mc.22501. Epub 2016 Jun 6.


Expression of PAM50 Genes in Lung Cancer: Evidence that Interactions between Hormone Receptors and HER2/HER3 Contribute to Poor Outcome.

Siegfried JM, Lin Y, Diergaarde B, Lin HM, Dacic S, Pennathur A, Weissfeld JL, Romkes M, Nukui T, Stabile LP.

Neoplasia. 2015 Nov;17(11):817-25. doi: 10.1016/j.neo.2015.11.002.


Functional analyses of ATM, ATR and Fanconi anemia proteins in lung carcinoma : ATM, ATR and FA in lung carcinoma.

Beumer JH, Fu KY, Anyang BN, Siegfried JM, Bakkenist CJ.

BMC Cancer. 2015 Oct 5;15:649. doi: 10.1186/s12885-015-1649-3.


Lung Cancer Risk Prediction Using Common SNPs Located in GWAS-Identified Susceptibility Regions.

Weissfeld JL, Lin Y, Lin HM, Kurland BF, Wilson DO, Fuhrman CR, Pennathur A, Romkes M, Nukui T, Yuan JM, Siegfried JM, Diergaarde B.

J Thorac Oncol. 2015 Nov;10(11):1538-45. doi: 10.1097/JTO.0000000000000666.


NF-κB1 p105 suppresses lung tumorigenesis through the Tpl2 kinase but independently of its NF-κB function.

Sun F, Qu Z, Xiao Y, Zhou J, Burns TF, Stabile LP, Siegfried JM, Xiao G.

Oncogene. 2016 May 5;35(18):2299-310. doi: 10.1038/onc.2015.299. Epub 2015 Aug 24.


Epigenetic Repression of CCDC37 and MAP1B Links Chronic Obstructive Pulmonary Disease to Lung Cancer.

Tessema M, Yingling CM, Picchi MA, Wu G, Liu Y, Weissfeld JL, Siegfried JM, Tesfaigzi Y, Belinsky SA.

J Thorac Oncol. 2015 Aug;10(8):1181-8. doi: 10.1097/JTO.0000000000000592.


15q12 variants, sputum gene promoter hypermethylation, and lung cancer risk: a GWAS in smokers.

Leng S, Liu Y, Weissfeld JL, Thomas CL, Han Y, Picchi MA, Edlund CK, Willink RP, Gaither Davis AL, Do KC, Nukui T, Zhang X, Burki EA, Van Den Berg D, Romkes M, Gauderman WJ, Crowell RE, Tesfaigzi Y, Stidley CA, Amos CI, Siegfried JM, Gilliland FD, Belinsky SA.

J Natl Cancer Inst. 2015 Feb 23;107(5). pii: djv035. doi: 10.1093/jnci/djv035.


Incidence of head and neck squamous cell carcinoma among subjects at high risk of lung cancer: results from the Pittsburgh Lung Screening Study.

Dixit R, Weissfeld JL, Wilson DO, Balogh P, Sufka P, Siegfried JM, Grandis JR, Diergaarde B.

Cancer. 2015 May 1;121(9):1431-5. doi: 10.1002/cncr.29189. Epub 2015 Jan 5.


Author's reply: To PMID 24808781.

Siegfried JS.

Tex Heart Inst J. 2014 Aug;41(4):455. No abstract available.


Matrix metalloproteinase-19 promotes metastatic behavior in vitro and is associated with increased mortality in non-small cell lung cancer.

Yu G, Herazo-Maya JD, Nukui T, Romkes M, Parwani A, Juan-Guardela BM, Robertson J, Gauldie J, Siegfried JM, Kaminski N, Kass DJ.

Am J Respir Crit Care Med. 2014 Oct 1;190(7):780-90. doi: 10.1164/rccm.201310-1903OC.


Inherited variation in the ATP-binding cassette transporter ABCB1 and survival after chemotherapy for stage III-IV lung cancer.

Weissfeld JL, Diergaarde B, Nukui T, Buch S, Pennathur A, Socinski MA, Siegfried JM, Romkes M.

J Thorac Oncol. 2014 Sep;9(9):1264-71. doi: 10.1097/JTO.0000000000000262.


Validation of a blood protein signature for non-small cell lung cancer.

Mehan MR, Williams SA, Siegfried JM, Bigbee WL, Weissfeld JL, Wilson DO, Pass HI, Rom WN, Muley T, Meister M, Franklin W, Miller YE, Brody EN, Ostroff RM.

Clin Proteomics. 2014 Aug 1;11(1):32. doi: 10.1186/1559-0275-11-32. eCollection 2014.


Co-targeting c-Met and COX-2 leads to enhanced inhibition of lung tumorigenesis in a murine model with heightened airway HGF.

Stabile LP, Rothstein ME, Gubish CT, Cunningham DE, Lee N, Siegfried JM.

J Thorac Oncol. 2014 Sep;9(9):1285-93. doi: 10.1097/JTO.0000000000000245.


Takotsubo cardiomyopathy as a sequela of elective direct-current cardioversion for atrial fibrillation.

Siegfried JS, Bhusri S, Guttenplan N, Coplan NL.

Tex Heart Inst J. 2014 Apr 1;41(2):184-7. doi: 10.14503/THIJ-12-3063. eCollection 2014 Apr.


Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer.

Gross ND, Bauman JE, Gooding WE, Denq W, Thomas SM, Wang L, Chiosea S, Hood BL, Flint MS, Sun M, Conrads TP, Ferris RL, Johnson JT, Kim S, Argiris A, Wirth L, Nikiforova MN, Siegfried JM, Grandis JR.

Clin Cancer Res. 2014 Jun 15;20(12):3289-98. doi: 10.1158/1078-0432.CCR-13-3360. Epub 2014 Apr 11.


Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment.

Ng YK, Lee JY, Supko KM, Khan A, Torres SM, Berwick M, Ho J, Kirkwood JM, Siegfried JM, Stabile LP.

Melanoma Res. 2014 Jun;24(3):207-18. doi: 10.1097/CMR.0000000000000060.


Estrongenic steroid hormones in lung cancer.

Siegfried JM, Stabile LP.

Semin Oncol. 2014 Feb;41(1):5-16. doi: 10.1053/j.seminoncol.2013.12.009. Epub 2013 Dec 12. Review.


Increased methylation of lung cancer-associated genes in sputum DNA of former smokers with chronic mucous hypersecretion.

Bruse S, Petersen H, Weissfeld J, Picchi M, Willink R, Do K, Siegfried J, Belinsky SA, Tesfaigzi Y.

Respir Res. 2014 Jan 9;15:2. doi: 10.1186/1465-9921-15-2.


Smoking out reproductive hormone actions in lung cancer.

Siegfried JM.

Mol Cancer Res. 2014 Jan;12(1):24-31. doi: 10.1158/1541-7786.MCR-13-0580. Epub 2014 Jan 7. Review.


RET rearrangements in lung adenocarcinoma and radiation.

Dacic S, Luvison A, Evdokimova V, Kelly L, Siegfried JM, Villaruz LC, Socinski MA, Nikiforov YE.

J Thorac Oncol. 2014 Jan;9(1):118-20. doi: 10.1097/JTO.0000000000000015.


Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503).

Brahmer JR, Lee JW, Traynor AM, Hidalgo MM, Kolesar JM, Siegfried JM, Guaglianone PP, Patel JD, Keppen MD, Schiller JH.

Eur J Cancer. 2014 Jan;50(2):302-8. doi: 10.1016/j.ejca.2013.10.006. Epub 2013 Nov 15.


Phase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung cancer.

Tarhini AA, Zahoor H, McLaughlin B, Gooding WE, Schmitz JC, Siegfried JM, Socinski MA, Argiris A.

Anticancer Res. 2013 Oct;33(10):4475-81.


Genetic variation in ESR2 and estrogen receptor-beta expression in lung tumors.

Song JY, Siegfried JM, Diergaarde B, Land SR, Bowser R, Stabile LP, Dacic S, Dhir R, Nukui T, Romkes M, Weissfeld JL.

Cancer Epidemiol. 2013 Aug;37(4):518-22. doi: 10.1016/j.canep.2013.03.020. Epub 2013 Apr 23.


Temporal relationship of conduction system disease and ventricular dysfunction in LMNA cardiomyopathy.

Brodt C, Siegfried JD, Hofmeyer M, Martel J, Rampersaud E, Li D, Morales A, Hershberger RE.

J Card Fail. 2013 Apr;19(4):233-9. doi: 10.1016/j.cardfail.2013.03.001.


The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma.

Villaruz LC, Socinski MA, Cunningham DE, Chiosea SI, Burns TF, Siegfried JM, Dacic S.

Cancer. 2013 Jun 15;119(12):2268-74. doi: 10.1002/cncr.28039. Epub 2013 Mar 22.


Sensitivity and specificity of short-duration transient visual evoked potentials (SD-tVEP) in discriminating normal from glaucomatous eyes.

Pillai C, Ritch R, Derr P, Gonzalez A, Kopko Cox L, Siegfried J, Liebmann JM, Tello C.

Invest Ophthalmol Vis Sci. 2013 Apr 23;54(4):2847-52. doi: 10.1167/iovs.12-10097.


Computerized identification of airway wall in CT examinations using a 3D active surface evolution approach.

Gu S, Fuhrman C, Meng X, Siegfried JM, Gur D, Leader JK, Sciurba FC, Pu J.

Med Image Anal. 2013 Apr;17(3):283-96. doi: 10.1016/ Epub 2012 Nov 29.


c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met.

Stabile LP, He G, Lui VW, Thomas S, Henry C, Gubish CT, Joyce S, Quesnelle KM, Siegfried JM, Grandis JR.

Clin Cancer Res. 2013 Jan 15;19(2):380-92. doi: 10.1158/1078-0432.CCR-12-1555. Epub 2012 Dec 4. Erratum in: Clin Cancer Res. 2013 Jul 1;19(13):3715. Thomas, Sufi [added].

Supplemental Content

Loading ...
Support Center